白蛋白结合型紫杉醇联合奈达铂治疗晚期食管癌的临床效果分析  

Clinical effect analysis of albumin-binding paclitaxel combined with nedaplatin in the treatment of advanced esophageal cancer

作　　者：邢磊[1] 叶惠兰 时海峰[1] 陈昌军[1] XING Lei;YE Hui-lan;SHI Hai-feng(People's Hospital of Sheyang County,Yancheng 224300,China)

机构地区：[1]江苏省射阳县人民医院,224300

出　　处：《中国现代药物应用》2024年第3期34-37,共4页Chinese Journal of Modern Drug Application

摘　　要：目的分析白蛋白结合型紫杉醇联合奈达铂治疗晚期食管癌的效果。方法66例组织学证实不可切除或者手术后复发或转移性晚期食管癌患者,采用随机数字表法分为对照组和观察组,各33例。对照组行紫杉醇+顺铂治疗,观察组行白蛋白结合型紫杉醇联合奈达铂治疗。对比两组患者临床疗效、生活质量评分、血清肿瘤标记物[糖类抗原125(CA125)、糖类抗原19-9(CA19-9)、鳞状细胞癌抗原(SCC)、癌胚抗原(CEA)]水平及不良反应发生情况。结果观察组客观缓解率(ORR)60.61%高于对照组的36.36%(P<0.05);两组疾病控制率(DCR)比较无差异(P>0.05)。观察组躯体功能、心理功能、社会功能以及物质生活评分分别为(88.80±4.50)、(89.05±4.05)、(88.20±3.50)、(87.80±5.02)分,高于对照组的(73.20±3.80)、(73.60±3.50)、(72.60±3.30)、(71.50±3.50)分(P<0.05)。两组治疗后CA125、CA19-9、SCC、CEA水平均较治疗前降低,且观察组CA125(8.08±1.60)U/ml、CA19-9(8.99±1.22)U/ml、SCC(1.08±0.20)μg/L、CEA(1.47±0.14)ng/ml低于对照组的(9.33±1.45)U/ml、(10.30±1.33)U/ml、(1.67±0.25)μg/L、(1.72±0.18)ng/ml(P<0.05)。观察组血小板减少、中性粒减少、恶心呕吐、肌痛、关节痛、周围神经病变发生率与对照组接近(P>0.05)。结论晚期食管癌患者予以白蛋白结合型紫杉醇联合奈达铂治疗可以提升治疗效果,促进患者血清肿瘤标志物水平及生活质量改善,且未增加不良反应。Objective To analyze the effect of albumin-binding paclitaxel combined with nedaplatin in the treatment of advanced esophageal cancer.Methods 66 patients with histologically proven unresectable or postoperative recurrent or metastatic advanced esophageal cancer were divided into a control group and an observation group by random number table method,each with 33 cases.The control group was treated with paclitaxel and cisplatin,while the observation group was treated with albumin-binding paclitaxel and nedaplatin.Both groups were compared in terms of clinical efficacy,quality of life score,levels of serum tumor markers[cancer antigen 125(CA125),cancer antigen 19-9(CA19-9),squamous cell carcinoma antigen(SCC),carcinoembryonic antigen(CEA)]and the occurrence of adverse reactions.Results The objective response rate(ORR)of the observation group was 60.61%,which was higher than 36.36%of the control group(P<0.05).There was no difference in disease control rate(DCR)between the two groups(P>0.05).The scores of physical function,psychological function,social function and material life in the observation group were(88.80±4.50),(89.05±4.05),(88.20±3.50)and(87.80±5.02)points,which were higher than(73.20±3.80),(73.60±3.50),(72.60±3.30)and(71.50±3.50)points of the control group(P<0.05).After treatment,the levels of CA125,CA19-9,SCC and CEA in both groups were lower than those before treatment;the observation group had CA125 of(8.08±1.60)U/ml,CA19-9 of(8.99±1.22)U/ml,SCC of(1.08±0.20)μg/L and CEA of(1.47±0.14)ng/ml,which were lower than(9.33±1.45)U/ml,(10.30±1.33)U/ml,(1.67±0.25)μg/L and(1.72±0.18)ng/ml in the control group(P<0.05).The incidence of thrombocytopenia,neutropenia,nausea and vomiting,myalgia,arthralgia and peripheral neuropathy in the observation group was similar to that in the control group(P>0.05).Conclusion The treatment of albumin-binding paclitaxel combined with nedaplatin in patients with advanced esophageal cancer can improve the therapeutic effect,promote the improvement of serum tumor mark

关 键 词：白蛋白结合型紫杉醇 奈达铂 晚期食管癌 血清标志物 

分 类 号：R735.1[医药卫生—肿瘤]